Download Your Exclusive Copy of the 2026 Agenda
Oligonucleotide R&D is accelerating rapidly, with billion-dollar investment from Novartis, Biogen and Roche signalling a clear shift toward CNS applications. For the first time, oligo therapeutics are enabling access to previously undruggable CNS targets - with emerging clinical success beginning to validate their potential.
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.